Search
1,2-dichlorobenzene
go.drugbank.com/drugs/DB13963ApprovedWithdrawn1,2-Dichlorobenzene, also named ortho-dichlorobenzene, is an organic compound. It is a non-polar colorless liquid that is miscible in most organic solvents. … insecticide and as an agent to remove carbon-based contamination from metal.
Categories: Compounds used in a research, industrial, or household settingNADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial
go.drugbank.com/bio_entities/BE0000037TargetHumansEssential for the catalytic activity and assembly of complex I (PubMed:22499348) … Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor
Synonyms: Complex I-23kDNADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial
go.drugbank.com/bio_entities/BE0000093TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-13kD-ANADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial
go.drugbank.com/bio_entities/BE0000307TargetEnzymeHumansEssential for the catalytic activity of complex I (PubMed:17275378) … Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor
Synonyms: Complex I-20kDAtaluren
go.drugbank.com/drugs/DB05016ApprovedWithdrawnAtaluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during
Trazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigationalreceptor inhibitor (SNRIs) in the treatment of depression. … [T646] It was initially granted FDA approval in 1981.[L3484]
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalmavorixafor is being investigated in these conditions. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.
Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-Luspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigational[A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin
Sucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalIt is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … , peptic ulcer disease, stress ulcer, in addition to dyspepsia [A177655].
Categories: Aluminum Complex